ALN-CFB Investigational complement factor B-silencing RNAi therapy licensed to Regeneron, undergoing Phase 1 development for paroxysmal nocturnal hemoglobinuria.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-CFB.
Add it to your Products I use list and share why you use it.